is a biotechnology company focused on the development of innovative cancer therapies. The company is dedicated to addressing unmet medical needs in oncology through the research and commercialization of novel drug candidates that target specific pathways associated with cancer growth and progression. By leveraging cutting-edge science and technology, Apollomics aims to create effective treatments that improve patient outcomes and quality of life for individuals battling various types of cancer. The company's strategic approach includes pursuing collaborations and partnerships to enhance its drug development pipeline.
Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC, pancreatic, and bile duct cancers.
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
